IL-5 CAR-T Cell Therapy (Zhejiang University)

N/A

Report date: 2025/12/04 20:00:08

Base Information

Drug NameIL-5 CAR-T Cell Therapy (Zhejiang University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-5 receptor subunit alpha inhibitors

TargetsInterleukin-5 receptor subunit alpha

Therapy Area/IndicationsHematologic DiseasesNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesZhejiang University

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University

Inactive CompaniesN/A

Active IndicationsHematologic DiseasesNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A